Richards Group (RIC) Q1 2026 earnings summary

Executive summary

• Achieved 5% year-over-year consolidated revenue growth to CAD 105.7 million, driven by healthcare segment acquisitions, organic growth in aesthetics and pharma, and new OEM product launches.

• Gross margin improved to 44%, with healthcare gross margin rising to 47% due to OEM shift, product mix, and pharmacy, dental, and surgical outperformance.

• EBITDA remained flat as higher operating expenses offset margin gains; EBITDA margin declined to 11.3% from 12%.

• Significant M&A activity included the CAD 13.5 million acquisition of PharmaSystems' CPG business and completion of a major share buyback.

• Investments in marketing, personnel, and technology supported new product launches and CRM implementation.

Financial highlights

• Healthcare segment contributed CAD 14.6 million in revenue growth (32.7%), offsetting a 17.2% decline in packaging revenue.

• Net income rose to $5.97 million from $5.11 million, with EPS up to $0.53 (basic) from $0.47.

• Adjusted EBITDAAL remained flat at $12.0 million, with healthcare up $3.3 million (61.0%) and packaging down $3.1 million (41.6%).

• Free cash flow conversion dropped to 63% from 81% due to higher interest, maintenance capital, taxes, and working capital needs.

• Leverage increased to 1.25x post-share buyback and M&A activity.

Outlook and guidance

• Packaging segment expected to remain challenged for the next three quarters due to inventory backlogs and macro headwinds.

• Management expects continued healthcare growth, both organic and via acquisitions, while packaging remains challenged by macroeconomic factors.

• Ongoing CapEx for ERP, infrastructure, and equipment, with focus on optimizing real estate and operational efficiencies.

• Strategic focus on organic growth, international expansion (notably LUVO brand in Europe by 2027), and new verticals such as dental and ortho.

• Financial performance expected to support working capital, capital expenditures, and dividends through 2026.